Verition Fund Management LLC Has $338,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Verition Fund Management LLC trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 66.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,337 shares of the company's stock after selling 8,404 shares during the period. Verition Fund Management LLC's holdings in AstraZeneca were worth $338,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Stratos Wealth Advisors LLC lifted its position in AstraZeneca by 2.0% in the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company's stock worth $522,000 after purchasing an additional 133 shares during the period. Carnegie Investment Counsel lifted its holdings in shares of AstraZeneca by 0.8% in the second quarter. Carnegie Investment Counsel now owns 17,269 shares of the company's stock valued at $1,347,000 after buying an additional 138 shares during the period. Crumly & Associates Inc. boosted its stake in AstraZeneca by 2.2% during the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company's stock valued at $518,000 after buying an additional 143 shares in the last quarter. Sunpointe LLC grew its holdings in AstraZeneca by 4.5% during the second quarter. Sunpointe LLC now owns 3,419 shares of the company's stock worth $267,000 after acquiring an additional 147 shares during the period. Finally, Argonautica Private Wealth Management Inc. raised its position in AstraZeneca by 4.0% in the second quarter. Argonautica Private Wealth Management Inc. now owns 3,874 shares of the company's stock worth $302,000 after acquiring an additional 149 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AZN. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a "sell" rating to a "hold" rating in a research report on Wednesday, November 6th. Erste Group Bank upgraded shares of AstraZeneca from a "hold" rating to a "buy" rating in a report on Wednesday, September 11th. Finally, UBS Group upgraded shares of AstraZeneca from a "sell" rating to a "neutral" rating in a research report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, AstraZeneca presently has a consensus rating of "Moderate Buy" and an average target price of $89.75.

AstraZeneca Stock Down 0.5 %

Shares of AZN traded down $0.36 during mid-day trading on Friday, reaching $66.58. The company's stock had a trading volume of 6,538,362 shares, compared to its average volume of 5,600,142. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company has a market cap of $206.44 billion, a price-to-earnings ratio of 31.86, a price-to-earnings-growth ratio of 1.19 and a beta of 0.45. The business has a fifty day moving average of $70.18 and a 200 day moving average of $76.71.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.03. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business's quarterly revenue was up 18.0% compared to the same quarter last year. During the same period last year, the company posted $0.87 EPS. As a group, analysts forecast that AstraZeneca PLC will post 4.11 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.